2 news items
Cerus Corporation Announces First Quarter 2024 Financial Results
CERS
2 May 24
to product safety, including the risk that the septic platelet transfusions may not be avoidable with the INTERCEPT Blood System; risks related to adverse
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
CERS
26 Mar 24
additional aging and stability data in order to satisfy regulators and maintain historical label claims; risks related to product safety; Cerus
- Prev
- 1
- Next